Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency.
about
The Landscape of Clinical Trials Evaluating the Theranostic Role of PET Imaging in Oncology: Insights from an Analysis of ClinicalTrials.gov DatabaseRegulatory review time for approval of oncology drugs in Japan between 2001 and 2014. Considerations of changes, factors that affect review time, and difference with the United States.Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan?Clinical trial designs to obtain marketing authorization of drugs for haematological malignancy in Japan, the EU and the US.Characteristics of clinical trials in rare vs. common diseases: A register-based Latvian study.
P2860
Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Acceptance of surrogate end po ...... he Japanese regulatory agency.
@en
Acceptance of surrogate end po ...... he Japanese regulatory agency.
@nl
type
label
Acceptance of surrogate end po ...... he Japanese regulatory agency.
@en
Acceptance of surrogate end po ...... he Japanese regulatory agency.
@nl
prefLabel
Acceptance of surrogate end po ...... he Japanese regulatory agency.
@en
Acceptance of surrogate end po ...... he Japanese regulatory agency.
@nl
P2860
P356
P1433
P1476
Acceptance of surrogate end po ...... he Japanese regulatory agency.
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDU500
P577
2014-10-30T00:00:00Z